

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	Cavaleri et al.	:	Confirmation No.: 6785
APPLICATION NO.:	10/829,068	:	Examiner: E. Peseliev
FILING DATE:	April 20, 2004	:	Group Art Unit: 1623
TITLE:	STABLE COMPOSITIONS OF DALBAVANCIN	:	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)

A Request for Continued Examination (RCE) for the subject application was filed on October 30, 2007; however, the RCE did not include a responsive amendment. Filed concurrently herewith is a response which meets the reply requirements under 37 C.F.R. § 1.111 and 37 C.F.R. § 1.114. It is Applicants' understanding that the time period for complying with the reply requirements for filing an RCE runs from the mailing date of the final office action, i.e., September 10, 2007. A response to the final office action was initially due three (3) months from the mailing date of the final office action, i.e., December 10, 2007. Therefore, the time period for filing a reply that meets the requirements under 37 C.F.R. § 1.111 and 37 C.F.R. § 1.114 was initially due three (3) months from the mailing date of the final office action, i.e., December 10, 2007.

Pursuant to the provisions of 37 C.F.R. §1.136(a), Applicants request that the time period for filing this response to the final office action be extended by one (1) month such that it expires on January 10, 2008.

Authorization is hereby provided to charge the amount of \$120.00, as stated under 37 C.F.R. §1.17, as well as any additional fees required, or to credit any overpayment to Applicants' Deposit Account No. 16-1445.

Respectfully submitted,

Date: January 3, 2008

/David L. Kershner/
David L. Kershner
Attorney for Applicant
Reg. No. 53,112

Pfizer Inc
Patent Dept. – 5th Floor
150 East 42nd Street
New York, NY 10017-5612
(212) 733-0538